Sutro Biopharma reports ~$333M cash, luvelta data in ovarian cancer, AML, NSCLC trials planned

SUTRO BIOPHARMA, INC.

Preliminary cash, equivalents, marketable securities ~$333M as of Dec 31, 2023; 0.7M shares of Vaxcyte stock valued ~$42M, funding into 2H2025.
Updated luvelta data in ovarian cancer: improved clinical outcomes and tolerability vs historical chemo; prophylactic G-CSF reduced neutropenia/dose delays.
Luvelta + bevacizumab showed clinical activity regardless of FolRα expression; preclinical NSCLC data showed single-dose activity and benefit with PD-1 blockade.
REFRαME-O1 registration trial in platinum-resistant ovarian cancer enrolling, Part 1 completion expected 1H2024, ~140 sites by end of 2024.
REFRαME-P1 trial initiation in pediatric CBF/GLIS AML planned 1H2024; IND submission in NSCLC planned 1H2024; endometrial cancer development ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.